Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Venlafaxine XR is FDA-approved for major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), and panic disorder. The immediate-release formulation is only approved for MDD. This makes venlafaxine XR one of the most broadly approved treatments for anxiety spectrum disorders.

Off-label uses include post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), attention-deficit/hyperactivity disorder (ADHD), hot flashes related to menopause or breast cancer treatment (an evidence-based use supported by major oncology guidelines), and migraine prophylaxis.

How It Works

Venlafaxine inhibits both SERT (serotonin transporter) and NET (norepinephrine transporter). However, its pharmacology is concentration-dependent: at lower concentrations, it functions primarily as a serotonin reuptake inhibitor (much like an SSRI), while meaningful norepinephrine reuptake inhibition emerges at higher concentrations. This dose-dependent dual action is a key pharmacological feature that distinguishes it from duloxetine, which shows more balanced dual inhibition throughout its range.

Venlafaxine is extensively metabolized in the liver by CYP2D6 to its primary active metabolite, O-desmethylvenlafaxine (ODV), also known as desvenlafaxine. ODV contributes substantially to the overall pharmacological activity and has its own branded formulation (Pristiq) used clinically.

For hot flash management, venlafaxine's noradrenergic effects are thought to stabilize the hypothalamic thermostat, reducing the frequency and severity of vasomotor symptoms without the hormonal risks of estrogen therapy.

Side Effects

Common

• Nausea (common early; usually resolves within 1–2 weeks)
• Insomnia
• Dizziness
• Dry mouth
• Constipation
• Increased sweating
• Sexual dysfunction (delayed orgasm, reduced libido)
• Elevated blood pressure (dose-dependent)

Serious

• Hypertension — noradrenergic activity causes clinically significant blood pressure increases, particularly at higher concentrations; regular monitoring required
• Serotonin syndrome — risk with concurrent serotonergic medications
• Discontinuation syndrome — very common and can be severe; brain zaps, extreme dizziness, nausea, paresthesias
• Suicidal ideation — black box warning in patients under 25
• Hyponatremia — SIADH mechanism; elderly most at risk
• Cardiac effects — small increases in heart rate; caution in pre-existing cardiac disease

Drug Interactions

Drug / Class	Interaction	Clinical Significance
MAO Inhibitors	Life-threatening serotonin syndrome	Contraindicated — 14-day washout required
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion)	Increased venlafaxine levels, reduced conversion to ODV; altered efficacy/toxicity	High — use with caution; monitor
Triptans (sumatriptan, rizatriptan)	Enhanced serotonergic effects; serotonin syndrome risk	Moderate — use cautiously; monitor
NSAIDs / Aspirin	Increased GI and systemic bleeding risk	Moderate — consider GI protection
Warfarin	Possible potentiation of anticoagulant effect	Moderate — monitor INR
Antihypertensives	Venlafaxine's pressor effects may counteract antihypertensive medications	Moderate — monitor blood pressure
Lithium	Additive serotonergic risk; monitor lithium levels	Moderate

Warnings & Contraindications

Contraindications: Concurrent or recent use of MAO inhibitors. Known hypersensitivity to venlafaxine or desvenlafaxine.

Blood pressure: Venlafaxine consistently raises blood pressure in a dose-dependent manner. Pre-existing hypertension should be controlled before initiating treatment. Blood pressure should be measured at each visit.

Discontinuation syndrome: Venlafaxine's short half-life makes discontinuation syndrome particularly common and severe. Even a missed dose may trigger symptoms. Tapering over weeks to months is recommended. In difficult cases, switching to fluoxetine (with its long half-life) and then tapering is a clinical strategy some prescribers use.

Narrow-angle glaucoma: Mydriasis has been reported with SNRIs; use with caution in patients with this condition.

Frequently Asked Questions

What is the difference between Effexor and Effexor XR?

Effexor (immediate-release) is taken multiple times daily and has a higher peak-to-trough plasma concentration variation, which is associated with more pronounced side effects and discontinuation symptoms. Effexor XR (extended-release) is taken once daily, produces a smoother plasma concentration curve, and is generally better tolerated. The XR formulation is also approved for anxiety disorders, whereas the immediate-release is not.

Why does venlafaxine cause such severe discontinuation symptoms?

Venlafaxine's parent compound has a short half-life of only about 5 hours. Even with the XR formulation, plasma levels drop relatively quickly between doses. Abrupt cessation leads to a sudden drop in serotonin and norepinephrine availability, producing withdrawal-like symptoms. Compared to long-acting SSRIs like fluoxetine, venlafaxine carries a substantially higher risk of discontinuation syndrome.

Can venlafaxine be used for hot flashes?

Yes. Venlafaxine is one of the most evidence-supported non-hormonal treatments for hot flashes associated with menopause or breast cancer treatment (particularly in women who cannot use estrogen). Major oncology organizations include it in guidelines for managing chemotherapy- and anti-estrogen-related vasomotor symptoms.

Does venlafaxine interact with tamoxifen like fluoxetine does?

Venlafaxine is a much weaker CYP2D6 inhibitor than fluoxetine or paroxetine. Because tamoxifen requires CYP2D6 activation to form its potent metabolite endoxifen, strong CYP2D6 inhibitors substantially reduce its efficacy. Venlafaxine is considered a safer antidepressant choice for breast cancer patients on tamoxifen.

→ SNRI Side Effects Guide → Depression Medications Guide → Anxiety Medications Guide